1
INTRODUCTION
25
2
EXECUTIVE SUMMARY
3
PREMIUM INSIGHTS
4
MARKET OVERVIEW
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
EUROPE AI ACT ACCELERATING DEMAND FOR COMPLIANT RADIOLOGY SOLUTIONS
4.2.1.2
EUROPEAN HEALTH DATA SPACE (EHDS) BOOSTING ACCESS TO STRUCTURED CROSS-BORDER IMAGING DATA
4.2.1.3
EUROPE FUNDING PROGRAMS SUPPORTING HEALTHCARE AI SCALE-UP
4.2.1.4
NATIONAL EHR/IMAGING DIGITIZATION PROGRAMS DRIVING PILOT DEPLOYMENTS IN PUBLIC SYSTEMS
4.2.1.5
OPERATIONAL PRESSURE FROM IMAGING BACKLOGS AND RADIOLOGIST CAPACITY GAPS
4.2.2
RESTRAINTS
4.2.2.1
COMPLEX EUROPEAN REGULATIONS INCREASING AI CERTIFICATION BURDENS
4.2.2.2
FRAGMENTED NATIONAL INTERPRETATIONS OF GDPR AND CONSENT LIMITING POOLED TRAINING DATASETS
4.2.3
OPPORTUNITIES
4.2.3.1
EHDS-ENABLED PAN-EU VALIDATION STUDIES AND REGULATORY EVIDENCE GENERATION
4.2.3.2
PROCUREMENT SCHEMES FAVORING COMPLIANT AI VENDORS
4.2.3.3
RISING DEMAND FOR PRIVACY-PRESERVING AI TECHNOLOGIES
4.2.3.4
CROSS-BORDER IMAGING COLLABORATIONS EXPANDING TRAINING DATASETS
4.2.4
CHALLENGES
4.2.4.1
REGULATORY/LEGAL UNCERTAINTY ABOUT LIABILITY AND CLINICAL ACCOUNTABILITY ACROSS MEMBER STATES
4.2.4.2
SLOW PUBLIC PROCUREMENT CYCLES AND LIMITED SCALE-UP CAPITAL FOR EUROPEAN MED-AI STARTUPS
4.3
UNMET NEEDS & WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC INDICATORS
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN HEALTHCARE IT INDUSTRY
5.3
VALUE CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.5
PRICING ANALYSIS
5.5.1
INDICATIVE PRICE FOR EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE SOLUTIONS, BY KEY PLAYER (2024)
5.5.2
INDICATIVE PRICE FOR EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE SOLUTIONS, BY COUNTRY (2024)
5.6
KEY CONFERENCES & EVENTS, 2026–2027
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8
INVESTMENT & FUNDING SCENARIO
5.9
CASE STUDY ANALYSIS
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.4
PATENT ANALYSIS
6.5
FUTURE APPLICATIONS
7
REGULATORY LANDSCAPE
7.1
REGULATIONS & COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY OFFERING (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
9.1
INTRODUCTION
9.2
INTEGRATED SOLUTIONS
9.3
NICHE/POINT SOLUTIONS
9.4
AI TECHNOLOGY
10
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY FUNCTION (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
10.1
INTRODUCTION
10.2
DIAGNOSIS & EARLY DETECTION
10.2.1
PRESCREENING
10.2.2.1
BY TECHNOLOGY
10.2.2.2
BY APPLICATION
10.2.3
DIAGNOSTIC IMAGING
10.2.3.1
BY APPLICATION
10.2.3.2
BY MODALITY
10.2.4
RISK ASSESSMENT & PATIENT STRATIFICATION
10.2.5
DRUG ALLERGY ALERTING
10.2.6
OTHERS
10.3
TREATMENT PLANNING & PERSONALIZATION
10.3.1
PERSONALIZED TREATMENT PLANNING
10.3.1.1
PRECISION MEDICINE & GENOMIC ANALYSIS
10.3.1.2
PREDICTIVE MODELS FOR TREATMENT RESPONSE
10.3.1.3
TREATMENT RECOMMENDATION SYSTEMS
10.3.2
PHARMACOLOGICAL THERAPY
10.3.2.1
DRUG RESPONSE PREDICTION
10.3.2.2
DOSING & ADMINISTRATION
10.3.2.3
OTHER PHARMACOLOGICAL THERAPIES
10.3.3
SURGICAL THERAPY
10.3.3.1
PREOPERATIVE IMAGING & 3D MODELING
10.3.3.2
INTRAOPERATIVE GUIDANCE & ROBOTICS
10.3.3.3
POSTOPERATIVE ANALYSIS & RECOVERY
10.3.4
RADIATION THERAPY
10.3.4.1
MOTION SYNCHRONIZATION & AUTO CONTOURING
10.3.4.2
REAL-TIME ADAPTIVE TREATMENT DELIVERY
10.3.4.3
RESPONSE ASSESSMENT & QUALITY ASSURANCE
10.3.4.4
OTHER RADIATION THERAPIES
10.3.5
BEHAVIORAL & PSCYCHOTHERAPY THERAPY
10.3.5.1
VIRTUAL COUNSELING & CHATBOTS
10.3.5.2
PROGRESS MONITORING & FEEDBACK
10.3.5.3
FOLLOW-UP & LONG-TERM SUPPORT
10.3.6
IMMUNOTHERAPY
10.3.6.1
REAL-TIME PATIENT DATA MONITORING (IMAGING SCANS, BLOOD BIOMARKERS, VITALS)
10.3.6.2
RESPONSE & SIDE-EFFECT PREDICTION
10.3.6.3
RELAPSE PREDICTION & LONG-TERM MANAGEMENT
10.3.7
OTHERS
10.4
PATIENT ENGAGEMENT & REMOTE MONITORING
10.4.1
SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE
10.4.2
TELEHEALTH & REMOTE PATIENT MONITORING
10.4.3
HEALTHCARE ASSISTANCE ROBOTS
10.4.4
MEDICATION REMINDERS
10.4.5
PATIENT EDUCATION & EMPOWERMENT
10.4.6
OTHER PATIENT ENGAGEMENT & REMOTE MONITORING FUNCTIONS
10.5
POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE
10.5.1
RECURRENCE MONITORING
10.5.2
LONG-TERM OUTCOME PREDICTION
10.5.3
MENTAL HEALTH & SUPPORT SYSTEMS
10.6
PHARMACY MANAGEMENT
10.6.1
EPRESCRIBING
10.6.2
MEDICATION MANAGEMENT
10.6.3
PHARMACY AUDIT & ANALYSIS
10.6.4
OTHER PHARMACY MANAGEMENT FUNCTIONS
10.7
DATA MANAGEMENT & ANALYTICS
10.8
ADMINISTRATIVE
10.8.1
PATIENT REGISTRATION & SCHEDULING
10.8.2
PATIENT ELIGIBILITY & AUTHORIZATION
10.8.3
BILLING & CLAIMS MANAGEMENT
10.8.4
WORKFORCE MANAGEMENT
10.8.5
SUPPLY CHAIN & INVENTORY MANAGEMENT
10.8.6
COMPLIANCE & DOCUMENTATION
10.8.7
HEALTHCARE WORKFLOW MANAGEMENT
10.8.8
ASSET MANAGEMENT
10.8.9
CUSTOMER RELATIONSHIP MANAGEMENT
10.8.10
FRAUD DETECTION & RISK MANAGEMENT
10.8.11
CYBERSECURITY
10.8.12
OTHER ADMINISTRATIVE FUNCTIONS
11
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY APPLICATION (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
11.1
INTRODUCTION
11.2
CLINICAL APPLICATIONS
11.3
NON-CLINICAL APPLICATIONS
12
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY DEPLOYMENT (USD MILLION) MODEL (MARKET SIZE & FORECAST TO 2030)
12.1
INTRODUCTION
12.2
ON-PREMISES MODEL
12.3
CLOUD-BASED MODEL
12.4
HYBRID MODEL
13
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY TOOL (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
13.1
INTRODUCTION
13.2
MACHINE LEARNING
13.2.1
DEEP LEARNING
13.2.1.1
CONVOLUTIONAL NEURAL NETWORKS (CNN)
13.2.1.2
RECURRENT NEURAL NETWORKS (RNN)
13.2.1.3
GENERATIVE ADVERSARIAL NETWORKS (GAN)
13.2.1.4
GRAPH NEURAL NETWORKS (GNN)
13.2.1.5
OTHER DEEP LEARNING TOOLS
13.2.2
SUPERVISED LEARNING
13.2.3
REINFORCEMENT LEARNING
13.2.4
UNSUPERVISED LEARNING
13.2.5
OTHER MACHINE LEARNING TOOLS
13.3
NATURAL LANGUAGE PROCESSING
13.3.1
SENTIMENT ANALYSIS
13.3.2
PATTERN & IMAGE RECOGNITION
13.3.3
AUTOCODING
13.3.4
CLASSIFICATION & CATEGORIZATION
13.3.5
TEXT ANALYTICS
13.3.6
SPEECH RECOGNITION
13.4
CONTEXT-AWARE COMPUTING
13.4.1
DEVICE CONTEXT
13.4.2
USER CONTEXT
13.4.3
PHYSICAL CONTEXT
13.5
GENERATIVE AI
13.6
COMPUTER VISION
13.7
IMAGE ANALYSIS
14
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY END USER (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
14.1
INTRODUCTION
14.2
HEALTHCARE PROVIDERS
14.2.1
HOSPITALS & CLINICS
14.2.2
AMBULATORY CARE CENTERS
14.2.3
HOME HEALTHCARE AGENCIES & ASSISTED LIVING FACILITIES
14.2.4
DIAGNOSTIC & IMAGING CENTERS
14.2.5
PHARMACIES
14.2.6
OTHERS HEALTHCARE PROVIDERS
14.3
HEALTHCARE PAYERS
14.3.1
PUBLIC PAYERS
14.3.2
PRIVATE PAYERS
14.4
PATIENTS
14.5
OTHER END USERS
15
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY COUNTRY (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
15.1
INTRODUCTION
15.7
REST OF EUROPE
16
COMPETITIVE LANDSCAPE
16.1
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
16.2
OVERVIEW
16.3
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
16.4
REVENUE ANALYSIS, 2020–2024
16.5
MARKET SHARE ANALYSIS,
16.6
BRAND/SOFTWARE COMPARISON
16.7
COMPANY EVALUATION MATRIX: KEY PLAYERS,
16.7.2
EMERGING LEADERS
16.7.3
PERVASIVE PLAYERS
16.7.4
PARTICIPANTS
16.7.5
COMPANY FOOTPRINT: KEY PLAYERS,
16.7.5.1
COMPANY FOOTPRINT
16.7.5.2
OFFERING FOOTPRINT
16.7.5.3
FUNCTION FOOTPRINT
16.7.5.4
APPLICATION FOOTPRINT
16.7.5.5
DEPLOYMENT FOOTPRINT
16.7.5.6
TOOL FOOTPRINT
16.7.5.7
END-USER FOOTPRINT
16.8
COMPANY EVAULATION MATRIX: STARTUPS/SMES,
16.8.1
PROGRESSIVE COMPANIES
16.8.2
DYNAMIC COMPANIES
16.8.3
RESPONSIVE COMPANIES
16.8.4
STARTING BLOCKS
16.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
16.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
16.8.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
16.9
COMPANY VALUATION & FINANCIAL METRICS
16.10
COMPETITIVE SCENARIO
16.10.1
PRODUCT LAUNCHES & UPGRADES
16.10.2
DEALS
16.10.3
EXPANSIONS
17
COMPANY PROFILES
17.1
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, SERVICES, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET LANDSCAPE
17.2
KEY PLAYERS
17.2.1
KONINKLIJKE PHILIPS N.V.
15.1.1.1
BUSINESS OVERVIEW
15.1.1.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
15.1.1.3
MNM VIEW
17.2.2
MICROSOFT CORPORATION
17.2.3
SIEMENS HEALTHINEERS AG
17.2.4
NVIDIA CORPORATION
17.2.5
EPIC SYSTEMS CORPORATION
17.2.6
GE HEALTHCARE
17.2.7
MEDTRONIC
17.2.8
ORACLE
17.2.9
BENEVOLENTAI
17.2.10
MERATIVE
17.2.11
17.2.12
JOHNSON & JOHNSON
17.2.13
AMAZON WEB SERVICES, INC.
17.2.14
SOPHIA GENETICS
17.2.15
COGNIZANT
17.2.16
TEMPUS
17.2.17
SOLVENTUM
17.2.18
ADA HEALTH GMBH
17.2.19
INFERMEDICA
17.2.20
VIZ.AI, INC.
17.3
OTHER PLAYERS
17.3.1
QURE.AI
17.3.3
ULTROMICS LIMITED.
17.3.4
OWKIN, INC
17.3.5
GLEAMER
18
RESEARCH METHODOLOGY
18.1
RESEARCH DATA
18.1.1
SECONDARY DATA
18.1.1.1
KEY DATA FROM SECONDARY SOURCES
18.1.2
PRIMARY DATA
18.1.2.1
KEY DATA FROM PRIMARY SOURCES
18.1.2.2
KEY PRIMARY PARTICIPANTS
18.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
18.1.2.4
KEY INDUSTRY INSIGHTS
18.2
MARKET SIZE ESTIMATION
18.2.1
BOTTOM-UP APPROACH
18.2.2
TOP-DOWN APPROACH
18.2.3
BASE NUMBER CALCULATION
18.3
MARKET FORECAST APPROACH
18.3.1
SUPPLY SIDE
18.3.2
DEMAND SIDE
18.4
DATA TRIANGULATION
18.5
FACTOR ANALYSIS
18.6
RESEARCH ASSUMPTIONS
18.7
RESEARCH LIMITATIONS & RISK ASSESSMENT
19.1
DISCUSSION GUIDE
19.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
CUSTOMIZATION OPTIONS
19.4
RELATED REPORTS
19.5
AUTHOR DETAILS
link